Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Takashi Higuchi; Norihiko Sugisawa; Jun Ho Park; Yu Sun; Guangwei Zhu; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Kentaro Igarashi; Michael Bouvet; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M. Hoffman

Translational Oncology (Oct 2020)

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Takashi Higuchi,
Norihiko Sugisawa,
Jun Ho Park,
Yu Sun,
Guangwei Zhu,
Norio Yamamoto,
Katsuhiro Hayashi,
Hiroaki Kimura,
Shinji Miwa,
Kentaro Igarashi,
Michael Bouvet,
Shree Ram Singh,
Hiroyuki Tsuchiya,
Robert M. Hoffman

Affiliations

Takashi Higuchi: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Norihiko Sugisawa: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Jun Ho Park: AntiCancer, Inc., San Diego, CA, USA
Yu Sun: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Guangwei Zhu: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Norio Yamamoto: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Katsuhiro Hayashi: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Hiroaki Kimura: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Shinji Miwa: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Kentaro Igarashi: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Michael Bouvet: Department of Surgery, University of California, San Diego, CA, USA
Shree Ram Singh: Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA; Corresponding authors.
Hiroyuki Tsuchiya: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan; Corresponding authors.
Robert M. Hoffman: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Correspondence to: R.M. Hoffman, AntiCancer, Inc., San Diego, CA, USA.

Journal volume & issue: Vol. 13, no. 10
p. 100826

Abstract

Read online

Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell line H1975, expressing red fluorescent protein (H1975-RFP), was orthotopically injected to the tibia of nude mice. The established mouse models were randomized into four treatment groups of nine mice: Control; BV alone; osimertinib alone; osimertinib and BV combination. The tumors were observed by non-invasive fluorescence imaging. Osimertinib, with or without BV, caused tumor regression, increased mouse survival, and bone remodeling in the bone metastasis models. These results suggest that osimertinib is a promising clinical option for NSCLS patients with bone metastasis.

Published in Translational Oncology

ISSN: 1944-7124 (Print); 1936-5233 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/translational-oncology/

About the journal

Abstract

Keywords